EP1534754A4 - Compositions bispecifiques de liaison d'antigene et methodes correspondantes - Google Patents

Compositions bispecifiques de liaison d'antigene et methodes correspondantes

Info

Publication number
EP1534754A4
EP1534754A4 EP03724219A EP03724219A EP1534754A4 EP 1534754 A4 EP1534754 A4 EP 1534754A4 EP 03724219 A EP03724219 A EP 03724219A EP 03724219 A EP03724219 A EP 03724219A EP 1534754 A4 EP1534754 A4 EP 1534754A4
Authority
EP
European Patent Office
Prior art keywords
bis
specific antigen
associated methods
binding compositions
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03724219A
Other languages
German (de)
English (en)
Other versions
EP1534754A2 (fr
Inventor
Lifen Ren-Heidenreich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roger Williams Medical Center
Original Assignee
Roger Williams Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roger Williams Medical Center filed Critical Roger Williams Medical Center
Publication of EP1534754A2 publication Critical patent/EP1534754A2/fr
Publication of EP1534754A4 publication Critical patent/EP1534754A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP03724219A 2002-04-23 2003-04-23 Compositions bispecifiques de liaison d'antigene et methodes correspondantes Ceased EP1534754A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37493002P 2002-04-23 2002-04-23
US374930P 2002-04-23
PCT/US2003/012772 WO2003090513A2 (fr) 2002-04-23 2003-04-23 Compositions bispecifiques de liaison d'antigene et methodes correspondantes

Publications (2)

Publication Number Publication Date
EP1534754A2 EP1534754A2 (fr) 2005-06-01
EP1534754A4 true EP1534754A4 (fr) 2005-12-21

Family

ID=29270571

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03724219A Ceased EP1534754A4 (fr) 2002-04-23 2003-04-23 Compositions bispecifiques de liaison d'antigene et methodes correspondantes

Country Status (3)

Country Link
EP (1) EP1534754A4 (fr)
AU (1) AU2003231092A1 (fr)
WO (1) WO2003090513A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005531A2 (fr) * 2002-07-05 2004-01-15 Roger Williams Medical Center Ciblage et depistage de cellules vers des organes et des tissus specifiques in vivo
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720353B2 (ja) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DE GAST G C ET AL: "Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies", JOURNAL OF HEMATOTHERAPY 1995 UNITED STATES, vol. 4, no. 5, 1995, pages 433 - 437, XP009055817, ISSN: 1061-6128 *
DE JONGE J ET AL: "In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 AUG 1998, vol. 161, no. 3, 1 August 1998 (1998-08-01), pages 1454 - 1461, XP002350359, ISSN: 0022-1767 *
GRUBER M ET AL: "EFFICIENT TUMOR CELL LYSIS MEDIATED BY A BISPECIFIC SINGLE CHAIN ANTIBODY EXPRESSED IN ESCHERICHIA COLI", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 152, no. 11, 1 June 1994 (1994-06-01), pages 5368 - 5374, XP000872832, ISSN: 0022-1767 *
HERLYN M ET AL: "CO 17-1A AND RELATED MONOCLONAL ANTIBODIES: THEIR PRODUCTION AND CHARACTERIZATION", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 5, no. SUPPL 1, July 1986 (1986-07-01), pages S03 - S10, XP008053117, ISSN: 0272-457X *
LOEFFLER ANJA ET AL: "A recombinant bispecific single-chain antibody, CD19 X CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 95, no. 6, 15 March 2000 (2000-03-15), pages 2098 - 2103, XP002299904, ISSN: 0006-4971 *
MACK M ET AL: "Biologic properties of a bispecific single-chain antibody directed agains 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 158, no. 8, April 1997 (1997-04-01), pages 3965 - 3970, XP002100040, ISSN: 0022-1767 *
SEGAL D M ET AL: "Bispecific antibodies in cancer therapy", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, vol. 11, no. 5, 1 October 1999 (1999-10-01), pages 558 - 562, XP004257585, ISSN: 0952-7915 *

Also Published As

Publication number Publication date
WO2003090513A2 (fr) 2003-11-06
AU2003231092A8 (en) 2003-11-10
EP1534754A2 (fr) 2005-06-01
WO2003090513A3 (fr) 2004-01-15
AU2003231092A1 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
DE602004004267D1 (de) Formtrennmittelzusammensetzung und verfahren damit
DE602005027205D1 (de) Nahrungsmittelzusammensetzungen und damit in zusammenhang stehende verfahren
DE60306687D1 (de) Mehrzweckpolymere, verfahren und zusammensetzungen
DE60327225D1 (de) Aripiprazol-komplex-formulierung und verfahren
EP1701725A4 (fr) Methodes et compositions
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
ATE435859T1 (de) Gyraseinhibitoren und deren verwendungen
DE60319310D1 (de) Gatterdielektrikum und Verfahren
DE60140895D1 (de) Zusammensetzung und verfahren
DE60229770D1 (de) Reibungsreduzierende zusammensetzung und verfahren
EP1680535A4 (fr) Procedes et compositions pour galvanoplastie
DE60333094D1 (de) Verbindungen, zusammensetzungen und verfahren
DE60317772D1 (de) Zweirichtungenmischrotor und verfahren
EP1599904A4 (fr) Structure et procede de lubistor lateral
DE60336039D1 (de) Verstellbares Bohrgerät und assoziiertes Verfahren
EP1455841A4 (fr) Compositions et methodes associees a l'osteopontine
DE602004027703D1 (de) Schwefelfreie zusammensetzung und schmiermittelzusammensetzung und verfahren davon
ATE417048T1 (de) N-ä3-(3-substituierte pyrazoloä1,5-aüpyrimidin-7- yl)phenylü-sulfonamide, und zusammensetzungen, und damit in zusammenhang stehende verfahren
DE60317443D1 (de) H-Brückenvorrichtung und Verfahren
DE60313337D1 (de) Aufprallschutz und dessen Verfahren
DE60327836D1 (de) PVD-Vorrichtung und Verfahren
ATE459726T1 (de) Verfahren und produkte
IS8489A (is) Umritunarstillar og aðferðir þeirra
FI20031330L (fi) Lajittelulaite ja -menetelmä
DE60230536D1 (de) Zusammensetzung und verfahren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050311

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20051107

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076288

Country of ref document: HK

17Q First examination report despatched

Effective date: 20060206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100124

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076288

Country of ref document: HK